研究者
J-GLOBAL ID：202001013498486321
更新日: 2025年05月09日
甲斐 正之
カイ マサユキ | Kai Masayuki
所属機関・部署：
職名：
Therapeutic Area Head (Hematology/Hem-oncology), Research Strategy
論文 (12件)：
-
Yuta Tezuka, Naoki Onoda, Tatsuya Morishima, Yoshiki Sumitomo, Keigo Nishii, Hitoshi Takizawa, Masayuki Kai. Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag. International journal of hematology. 2024
-
Yuta Izumi, Masashi Kanayama, Zhongchuzi Shen, Masayuki Kai, Shunsuke Kawamura, Megumi Akiyama, Masahide Yamamoto, Toshikage Nagao, Keigo Okada, Norihiko Kawamata, et al. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy. Frontiers in immunology. 2021. 12. 618081-618081
-
Yoshiyuki Kiyasu, Kenji Kawada, Hideyo Hirai, Ryotaro Ogawa, Keita Hanada, Hideyuki Masui, Gen Nishikawa, Takamasa Yamamoto, Rei Mizuno, Yoshiro Itatani, et al. Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice. Cancer letters. 2020. 487. 53-62
-
泉 湧太, 金山 剛士, 秋山 めぐみ, 甲斐 正之, 沈 鐘楚子, 川又 紀彦, 樗木 俊聡. 単球性白血病の新規治療戦略としての単球系制限抗原の標的化(Targeting monocyte lineage-restricted antigen as a novel therapeutic strategy for monocytic leukemia). 日本病理学会会誌. 2020. 109. 1. 304-304
-
Ved P Sharma, Robert Eddy, David Entenberg, Masayuki Kai, Frank B Gertler, John Condeelis. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Current biology : CB. 2013. 23. 21. 2079-89
もっと見る
MISC (4件)：
-
泉 湧太, 金山 剛士, 秋山 めぐみ, 甲斐 正之, 沈 鐘楚子, 川又 紀彦, 樗木 俊聡. 単球性白血病の新規治療戦略としての単球系制限抗原の標的化(Targeting monocyte lineage-restricted antigen as a novel therapeutic strategy for monocytic leukemia). 日本病理学会会誌. 2020. 109. 1. 304-304
-
甲斐 正之. 抗MPLアゴニスト抗体のヒト造血細胞に対するin vivo作用検討. 血液・腫瘍科. 2009. 59. 1. 73-77
-
甲斐 正之, 片岡 之郎. BIO R&D 定常領域サブクラスの変換による抗トロンボポエチン受容体アゴニスト抗体の活性向上. バイオインダストリー. 2008. 25. 7. 83-91
-
Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, Kumi Tsuruhata, Chisato Endo, Mari Muto, Chie Emuta, Yukiko Chisaka, Munetake Shimabe, Hiroshi Miyazaki, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. BLOOD. 2006. 108. 11. 336A-337A
特許 (13件)：
書籍 (1件)：
-
機能性DDSキャリアの製剤設計
シーエムシー出版 2008 ISBN:9784781300528
講演・口頭発表等 (2件)：
-
Hematopoietic stem cell-based cell and gene therapy beyond monogenic diseases
(UC San Diego inaugural Gene Therapy Initiative Symposium 2024)
-
Anti-thrombopoietin receptor agonist antibodies improved by domain-sublcass conversion
(2008)
学位 (1件)：
経歴 (5件)：
- 2025/01 - 現在 Kyowa Kirin, Inc. - U.S. Therapeutic Area Head (Hematology/Hem-oncology), Research Strategy
- 2004/04 - 現在 協和キリン株式会社
- 2024/01 - 2024/12 Kyowa Kirin, Inc. - U.S. Vice President, Head of Research
- 2023/10 - 2023/12 Kyowa Kirin, Inc. Executive Director of Research
- 2010/06 - 2011/11 Massachusetts Institute of Technology Koch Institute of Integrated Cancer Research Visiting Scientist
前のページに戻る
